Loading news...
Citigroup Inc. reduced its position in shares of Teleflex Incorporated (NYSE: TFX) by 40.0% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,004 shares of the medical technology company's stock after selling 14,020 shares during the period. Citigroup
Focus Partners Advisor Solutions LLC acquired a new position in shares of Teleflex Incorporated (NYSE: TFX) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 12,178 shares of the medical technology company's stock, valued at approximately $1,362,000. A number of
Teleflex faces a complex transition after divesting major business units at low multiples, creating uncertainty around future earnings power. Teleflex now trades at 17–18x forward earnings with a strong balance sheet and mid-single-digit organic growth, yet recent strategic actions have impaired conviction. 2026 guidance is clouded by stranded costs and transition agreements, but normalized earnings could reach $8–9 per share, offering potential upside above $150.
Teleflex Q4 earnings and revenues miss estimates as margins shrink, but shares rise 1.7% after hours amid 2026 growth guidance and portfolio reshuffle.
Teleflex Incorporated (TFX) Q4 2025 Earnings Call Transcript
Teleflex (TFX) came out with quarterly earnings of $1.93 per share, missing the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.89 per share a year ago.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable March 31, 2026, to shareholders of record at the close of business on March 6, 2026. Additional information about Teleflex can be obtained from the company's website at teleflex.com. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven b.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the year ended December 31, 2025. Full year 2025 continuing operations financial summary1 GAAP revenue from continuing operations of $1,992.7 million, up 17.2% compared to the prior year period1 Adjusted revenue from continuing operations of $1,983.7 million, up 16.3% compared to the prior year period, and up 15.4% on an adjusted constant currency basis2 GAAP diluted EPS from con.
Beyond analysts' top-and-bottom-line estimates for Teleflex (TFX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Teleflex (TFX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter 2025 financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, February 26, 2026. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company's website, teleflex.com. An audio replay of the call will be available be.
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Tejara Capital bought 69,700 Teleflex shares in the fourth quarter; the estimated trade size was $8.45 million based on quarterly average prices. Meanwhile, the quarter-end position value rose by $8.50 million, reflecting both share additions and price movement.
NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
This medical technology company supplies single-use devices for critical care and surgery to hospitals and healthcare providers worldwide.
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Cooke and Bieler LP boosted its holdings in shares of Teleflex Incorporated (NYSE: TFX) by 1.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,220,637 shares of the medical technology company's stock after acquiring an additional 14,673 shares during the quarter. Teleflex
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated (“Teleflex” or the “Company”) (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.